Latest news with #NKTR
Yahoo
03-08-2025
- Business
- Yahoo
Nektar Therapeutics (NASDAQ:NKTR) is a favorite amongst institutional investors who own 53%
Key Insights Significantly high institutional ownership implies Nektar Therapeutics' stock price is sensitive to their trading actions A total of 17 investors have a majority stake in the company with 50% ownership Insiders have been selling lately We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Every investor in Nektar Therapeutics (NASDAQ:NKTR) should be aware of the most powerful shareholder groups. With 53% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Hence, having a considerable amount of institutional money invested in a company is often regarded as a desirable trait. Let's delve deeper into each type of owner of Nektar Therapeutics, beginning with the chart below. Check out our latest analysis for Nektar Therapeutics What Does The Institutional Ownership Tell Us About Nektar Therapeutics? Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. Nektar Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Nektar Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 13% of Nektar Therapeutics shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Our data shows that Charles Schwab Investment Management, Inc. is the largest shareholder with 8.3% of shares outstanding. BVF Partners L.P. is the second largest shareholder owning 7.4% of common stock, and Millennium Management LLC holds about 5.4% of the company stock. A closer look at our ownership figures suggests that the top 17 shareholders have a combined ownership of 50% implying that no single shareholder has a majority. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Nektar Therapeutics The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our data suggests that insiders own under 1% of Nektar Therapeutics in their own names. It has a market capitalization of just US$397m, and the board has only US$4.0m worth of shares in their own names. Many investors in smaller companies prefer to see the board more heavily invested. You can click here to see if those insiders have been buying or selling. General Public Ownership With a 33% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Nektar Therapeutics. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. Next Steps: While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Nektar Therapeutics has 4 warning signs (and 3 which can't be ignored) we think you should know about. But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Insider
25-06-2025
- Business
- Business Insider
Why Is Nektar Therapeutics Stock (NKTR) Up 110% Today?
Nektar Therapeutics (NKTR) stock surged on Tuesday after the California-based biopharmaceutical company announced results from its Phase 2b study of rezpegaldesleukin. This is a treatment in development for patients with eczema. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Results from the clinical trial were positive, with the primary endpoint met. On top of that, all of the study's secondary endpoints were also achieved. Nektar Therapeutics will continue treatment of patients in this study, with topline results expected in Q4 2025 and additional data in Q1 2026. Nektar Therapeutics stock soared 110.17% on Tuesday alongside its clinical trial results. That builds on a 12.1% rally yesterday. However, the shares are still down 31.61% year-to-date and 40.56% over the past 12 months. Is Nektar Therapeutics Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Nektar Therapeutics is Strong Buy, based on four Buy and one Hold rating over the past three months. With that comes an average NKTR stock price target of $73.13, representing a potential 666.56% upside for the shares.
Washington Post
08-05-2025
- Business
- Washington Post
Nektar: Q1 Earnings Snapshot
SAN FRANCISCO — SAN FRANCISCO — Nektar Therapeutics (NKTR) on Thursday reported a loss of $50.9 million in its first quarter. On a per-share basis, the San Francisco-based company said it had a loss of 24 cents. Losses, adjusted for non-recurring costs, came to 22 cents per share. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.
Yahoo
11-04-2025
- Business
- Yahoo
Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00
Shares of Nektar Therapeutics (NKTR, Financials) rose 26.21% to $0.50 as of 11:36 a.m. ET Friday after Jefferies upgraded the stock from Hold to Buy and increased its price target from $1.00 to $2.00. The firm's revised rating comes ahead of the expected second-quarter topline data from a Phase 2b study of Rezpeg, Nektar's experimental treatment for atopic dermatitis. Warning! GuruFocus has detected 7 Warning Signs with NKTR. The company has lost over 63% of its market value in the past six months, but Jefferies analyst Roger Song cited encouraging results from a Phase 1b trial, which showed a favorable safety and efficacy profile for Rezpeg, an IL-2 Treg stimulator. Song said the drug's novel mechanism of action sets it apart from other current and pipeline treatments in the space. According to Jefferies, the significant negative enterprise value and high liquidityreflected in a current ratio of 4.26support a more favorable risk-reward scenario. Nektar's market capitalization is currently around $93 million. The firm also pointed to Nektar's cash position of $269.1 million at the end of 2024, which is expected to fund operations through the fourth quarter of 2026. The company recently beat consensus earnings expectations, reporting a fourth-quarter 2024 earnings per share of $0.03, compared with an anticipated loss of $0.16. However, revenue for the quarter came in slightly below forecast at $29.2 million versus $29.81 million. Nektar has entered a $75 million equity distribution agreement to support its financial flexibility. The biotech firm is progressing with clinical development for Rezpeg, which is also being studied for alopecia areata and Type 1 diabetes. Other analysts have issued varying outlooks. Oppenheimer raised its rating to Outperform with a $6.00 price target, while BTIG maintained a Neutral stance with a $4.00 target. This article first appeared on GuruFocus.
Yahoo
22-03-2025
- Business
- Yahoo
Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil
We recently published a list of . In this article, we are going to take a look at where Nektar Therapeutics (NASDAQ:NKTR) stands against other stocks that Wall Street is calling bullish amid market turmoil. The S&P 500 is down 8.6% in a month while the Nasdaq has lost nearly 13%. Markets continue to scare retail investors as stock after stock struggles to deal with the aftermath of Donald Trump's unpredictable and aggressive policies. While it is advisable to stay out of the market till the dust settles, one also can't deny that it is times like these that bring opportunities. We decided to come up with a list of stocks that are expected to go up even in the existing gloomy environment. To come up with the list of 10 stocks that Wall Street is bullish on, we looked at stocks that were recently upgraded by analysts and have performed well in the last 5 days of trading. A scientist in lab coat testing a new biopharmaceutical drug on a microscope. Nektar Therapeutics (NASDAQ:NKTR) operates as a biopharmaceutical company that discovers and develops therapies to treat autoimmune disorders. Its products include NKTR-358, PEG-CSF1, and others. The company's stock price gained 6% in the previous year despite a downturn in the second half of the year. Based on 9 different analyst ratings, NKTR has the highest target price of $7 which means it has the potential to grow more than six times higher from the current levels if the bull thesis holds true. The stock is currently trading at $0.91 which is 9.97% below the lowest Wall Street price target of $1. Nektar Therapeutics (NASDAQ:NKTR) was recently upgraded by Oppenheimer from Perform to Outperform with a price target of $6. According to the analysts, the company's stock valuation was attractive prior to the mid-stage trial results for its eczema therapy Rezpegaldesleukin. Analyst Jay Olson emphasized that Rezpeg's distinctive profile places it in a strong position to grow in an expanding market and could offer significant benefits for eczema patients. Despite risks, investors could make 6x their money in this stock. Overall, NKTR ranks 6th on our list of stocks that Wall Street is calling bullish amid market turmoil. While we acknowledge the potential of NKTR as a leading investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as NKTR but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
